http://orcid.org/0000-0001-5057-4457
About the Authors
- Iana H. Haralambieva
-
Roles Conceptualization, Data curation, Writing – original draft, Writing – review & editing
Affiliation Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America
- Richard B. Kennedy
-
Roles Conceptualization, Formal analysis, Writing – original draft, Writing – review & editing
Affiliation Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America
- Whitney L. Simon
-
Roles Data curation, Writing – original draft
Affiliation Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America
- Krista M. Goergen
-
Roles Formal analysis, Writing – original draft, Writing – review & editing
Affiliation Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America
- Diane E. Grill
-
Roles Conceptualization, Formal analysis, Writing – original draft, Writing – review & editing
Affiliation Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America
- Inna G. Ovsyannikova
-
Roles Conceptualization, Data curation, Formal analysis, Writing – original draft, Writing – review & editing
Affiliation Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America
- Gregory A. Poland
-
Roles Conceptualization, Funding acquisition, Supervision, Writing – original draft, Writing – review & editing
* E-mail: poland.gregory@mayo.edu
Affiliation Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America
Competing Interests
Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc., Avianax, Dynavax, Novartis Vaccines and Therapeutics, Adjuvance Technologies, Seqirus, and Protein Sciences. Drs. Poland and Ovsyannikova hold three patents related to vaccinia and measles peptide research. Dr. Kennedy has received funding from Merck Research Laboratories to study waning immunity to mumps vaccine. This does not alter our adherence to PLOS ONE policies on sharing data and materials.